Intrexon Corp (NASDAQ:XON) traded down 5.4% during mid-day trading on Wednesday . The company traded as low as $6.75 and last traded at $6.80, 1,540,846 shares were traded during trading. An increase of 8% from the average session volume of 1,433,065 shares. The stock had previously closed at $7.19.

Separately, BidaskClub raised shares of Intrexon from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Intrexon presently has an average rating of “Hold” and a consensus target price of $17.00.

The business’s fifty day moving average price is $5.91 and its 200-day moving average price is $6.22. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.71 and a current ratio of 1.92. The stock has a market cap of $1.01 billion, a PE ratio of -4.26 and a beta of 2.26.

Intrexon (NASDAQ:XON) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. The firm had revenue of $23.04 million for the quarter, compared to the consensus estimate of $32.16 million. Intrexon had a negative net margin of 393.13% and a negative return on equity of 45.51%. Analysts forecast that Intrexon Corp will post -0.96 earnings per share for the current fiscal year.

In related news, insider Donald P. Lehr sold 4,830 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $5.60, for a total value of $27,048.00. Following the transaction, the insider now owns 81,156 shares of the company’s stock, valued at $454,473.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Thomas Bostick sold 6,533 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $5.83, for a total transaction of $38,087.39. Following the completion of the transaction, the chief operating officer now directly owns 80,813 shares in the company, valued at approximately $471,139.79. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,066 shares of company stock worth $213,533. Insiders own 44.00% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its holdings in Intrexon by 1.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 417,274 shares of the biotechnology company’s stock valued at $3,197,000 after purchasing an additional 5,612 shares in the last quarter. LPL Financial LLC lifted its holdings in Intrexon by 15.8% during the second quarter. LPL Financial LLC now owns 19,494 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 2,659 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Intrexon by 9.0% during the second quarter. Bank of New York Mellon Corp now owns 339,553 shares of the biotechnology company’s stock valued at $2,602,000 after purchasing an additional 27,968 shares in the last quarter. Northern Trust Corp lifted its holdings in Intrexon by 1.7% during the second quarter. Northern Trust Corp now owns 936,605 shares of the biotechnology company’s stock valued at $7,175,000 after purchasing an additional 15,264 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Intrexon by 46.3% during the second quarter. Parametric Portfolio Associates LLC now owns 85,275 shares of the biotechnology company’s stock valued at $653,000 after purchasing an additional 27,002 shares in the last quarter. 76.33% of the stock is currently owned by institutional investors.

Intrexon Company Profile (NASDAQ:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Recommended Story: How to interpret the current ratio

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.